

NDA 211970 / S-002

SUPPLEMENT APPROVAL

Sarepta Therapeutics, Inc.
Attention: Carl Denny
Executive Director, Regulatory Affairs
215 First Street, Suite 415
Cambridge, MA 02142

Dear Mr. Denny:

Please refer to your supplemental new drug application (sNDA) dated August 12, 2020, received August 12, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vyondys 53 (golodirsén) injection.

This Prior Approval supplemental new drug application provides for changes to the language in the Prescribing Information in Dosage and Administration (Subsection 2.1) and Warnings and Precautions (Subsection 5.2) to update the language to be consistent with current recommendations for monitoring for kidney toxicity and regarding timing of urine samples because of a potential test interference, Pharmacodynamics (Subsection 12.2) regarding the dystrophin quantitation assay, and Clinical Studies (Section 14) to specify the “Sarepta western blot” assay.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Michael Matthews, Regulatory Project Manager, via email at Michael.Matthews@fda.hhs.gov or phone at (301) 796-3047.

Sincerely,

{See appended electronic signature page}

Teresa Buracchio, MD
Deputy Director
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TERESA J BURACCHIO
02/11/2021 01:22:14 PM